Cargando…

The Genetic Basis of Moyamoya Disease

Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral an...

Descripción completa

Detalles Bibliográficos
Autores principales: Mertens, R., Graupera, M., Gerhardt, H., Bersano, A., Tournier-Lasserve, E., Mensah, M. A., Mundlos, S., Vajkoczy, P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766392/
https://www.ncbi.nlm.nih.gov/pubmed/34529262
http://dx.doi.org/10.1007/s12975-021-00940-2
_version_ 1784634519628808192
author Mertens, R.
Graupera, M.
Gerhardt, H.
Bersano, A.
Tournier-Lasserve, E.
Mensah, M. A.
Mundlos, S.
Vajkoczy, P.
author_facet Mertens, R.
Graupera, M.
Gerhardt, H.
Bersano, A.
Tournier-Lasserve, E.
Mensah, M. A.
Mundlos, S.
Vajkoczy, P.
author_sort Mertens, R.
collection PubMed
description Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral angiography. These pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive screening and possibly the  development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only.
format Online
Article
Text
id pubmed-8766392
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-87663922022-02-02 The Genetic Basis of Moyamoya Disease Mertens, R. Graupera, M. Gerhardt, H. Bersano, A. Tournier-Lasserve, E. Mensah, M. A. Mundlos, S. Vajkoczy, P. Transl Stroke Res Review Article Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral angiography. These pathological alterations of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to limit the stenotic lesions or the development of a collateral network is available, the only treatment established so far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be replicated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells, cytokines and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive screening and possibly the  development of new therapeutic approaches. This review focuses on the genetic basis of primary MMD only. Springer US 2021-09-16 2022 /pmc/articles/PMC8766392/ /pubmed/34529262 http://dx.doi.org/10.1007/s12975-021-00940-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Review Article
Mertens, R.
Graupera, M.
Gerhardt, H.
Bersano, A.
Tournier-Lasserve, E.
Mensah, M. A.
Mundlos, S.
Vajkoczy, P.
The Genetic Basis of Moyamoya Disease
title The Genetic Basis of Moyamoya Disease
title_full The Genetic Basis of Moyamoya Disease
title_fullStr The Genetic Basis of Moyamoya Disease
title_full_unstemmed The Genetic Basis of Moyamoya Disease
title_short The Genetic Basis of Moyamoya Disease
title_sort genetic basis of moyamoya disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8766392/
https://www.ncbi.nlm.nih.gov/pubmed/34529262
http://dx.doi.org/10.1007/s12975-021-00940-2
work_keys_str_mv AT mertensr thegeneticbasisofmoyamoyadisease
AT grauperam thegeneticbasisofmoyamoyadisease
AT gerhardth thegeneticbasisofmoyamoyadisease
AT bersanoa thegeneticbasisofmoyamoyadisease
AT tournierlasservee thegeneticbasisofmoyamoyadisease
AT mensahma thegeneticbasisofmoyamoyadisease
AT mundloss thegeneticbasisofmoyamoyadisease
AT vajkoczyp thegeneticbasisofmoyamoyadisease
AT mertensr geneticbasisofmoyamoyadisease
AT grauperam geneticbasisofmoyamoyadisease
AT gerhardth geneticbasisofmoyamoyadisease
AT bersanoa geneticbasisofmoyamoyadisease
AT tournierlasservee geneticbasisofmoyamoyadisease
AT mensahma geneticbasisofmoyamoyadisease
AT mundloss geneticbasisofmoyamoyadisease
AT vajkoczyp geneticbasisofmoyamoyadisease